Integrative Oncology Trials Lorenzo Cohen, PhD Director, Integrative Medicine Program.

Slides:



Advertisements
Similar presentations
A Retrospective Review Investigating the Feasibility of Acupuncture as a Supportive Care Agent in Children with Cancer Kathy Taromina, MS, LAc, Diane Rooney,
Advertisements

A Phase III Prospective Randomized Trial of Acupuncture for Treatment of Radiation-Induced Xerostomia in Patients with Head and Neck Cancer CCOP Investigators’
New England Journal of Medicine October 18;367: Relapse Risk after Discontinuation of Risperidone in Alzheimer’s disease Molly Moncrieff.
Richard T. Lee, MD Assistant Professor Medical Director, Integrative Medicine Program March 4, 2011.
Clinical Significance
The Cochrane Reviews of Acupuncture Doris Hubbs, MD, FACP April 26, 2013.
Botulinum toxin type A for the prevention of headaches in adults with chronic migraine.
Modified Megestrol The Clinical Trials by : Carolina R. Akib
Visit our websites: PhD Study: Evaluation of the Efficacy of the Incredible.
Are You Ready to Assess For Distress? Lee Tremback, MA, LCSW, OSW-C Oncology Social Worker Eastern Connecticut Cancer Institute John A. DeQuattro Cancer.
Clinical Trials The Way We Make Progress Against Disease.
Presentation on ESPRIT & STALWART Cycling Washington ICC Group Meeting, June 2007 CCG Training Session Prepared by: Dale C. Sattergren ESPRIT & STALWART.
Integrative Therapy for Chronic Neutropenia: A Wellness Strategy Mary Ann Bonilla, MD Medical Director, Integrative Therapies St. Joseph ‘s Regional Medical.
MANAGING FATIGUE during treatment Since fatigue is the most common symptom in people receiving chemotherapy, patients should learn ways to manage the fatigue.
A Meta Analysis of Risk of Cardiovascular Events in Patients with Metastatic Breast Cancer (MBC) Treated with Anti Vascular Endothelial Growth Factor (VEGF)
Phase III Study Comparing Gemcitabine plus Cetuximab versus Gemcitabine in Patients with Locally Advanced or Metastatic Pancreatic Adenocarcinoma Southwest.
Complementary and Alternative Healing Chapter 33
Clinical Trials. What is a clinical trial? Clinical trials are research studies involving people Used to find better ways to prevent, detect, and treat.
Exercise Management Cancer. Pathophysiology Cancer is not a single disease; it is a collection of hundreds of diseases that share the common feature of.
Testing People Scientifically.  Clinical trials are research studies in which people help doctors and researchers find ways to improve health care. Each.
Overview of Phase I Data: Approach and Findings Gary Bess Associates April 15, 2009.
Mindful Exercise, Quality of Life, and Cancer A Mindfulness- Based Exercise Rehabilitation Program for Women with Breast Cancer Anna M. Tacon, Ph. D.
Progesterone and Traumatic Brain Injury. from: Progesterone is a female hormone important for the regulation of.
A Phase II Study to Evaluate the Safety and Toxicity of Sparing Radiation to the Pathologic N0 Side of the Neck in Squamous Cell.
Taxane-pretreated metastatic breast cancer (MBC): investigational agents TTP = median time to disease progression OS = median overall survival.
Amany M. Shebl Professor Of Medical-surgical Nursing Dean. Nursing Faculty, Mansoura University, Egypt.
Clinical Trial Designs An Overview. Identify: condition(s) of interest, intended population, planned treatment protocols Recruitment of volunteers: volunteers.
ACRIN 6685 Overview ACRIN 6685 A Multi-center Trial of FDG-PET/CT Staging of Head and Neck Cancer and its Impact on the N0 Neck Surgical Treatment in Head.
Predictors of Cancer-related Pain Improvement over 12 Months Hsiao-Lan Wang, PhD, RN, CMSRN, HFS Assistant Professor University of South Florida September,
Prevention of Pegfilgrastim-induced Bone Pain (PIP): A URCC CCOP Randomized, Double-blind, Placebo-controlled Trial of 510 Cancer Patients Jeffrey J. Kirshner,
Treating Chronic Pain in Adolescents Amanda Bye, PsyD, Behavioral Medicine Specialist Collaborative Family Healthcare Association 15 th Annual Conference.
Building Clinical Infrastructure and Expert Support Michael Steinberg, MD, FACR ULAAC Disparity Project Centinela/Freeman Health System.
Barb Supanich, RSM, MD, FAAHPM Holy Cross IP Palliative Care Team November 11, 2010.
SARC: Participation and Protocol / Concept Review Robert Maki, MD PhD Memorial Sloan-Kettering Cancer Center.
The COMBINE Study: Design and Methodology Stephanie S. O’Malley, Ph.D. for The COMBINE Study Research Group JAMA Vol. 295, , 2006 (May 3 rd.
Susan M Cohen, DSN, FAAN 1 Susan Sereika, PhD 1, Margaret Stubbs, PhD 2, Kathleen Spadaro, PhD 2 Catherine Bender, PhD, FAAN 1 Carol Greco, PhD 1 1 University.
BASED ON PROTOCOL VERSION 1 SEPTEMBER 2012 A new study evaluating an investigational drug to treat patients with HER2-positive metastatic gastroesophageal.
How To Design a Clinical Trial
Rituximab plus Lenalidomide Improves the Complete Remission Rate in Comparison with Rituximab Monotherapy in Untreated Follicular Lymphoma Patients in.
Lesson 1. I. Brief instructor and class member introductions  Class members include why they enrolled in the class and what they want to learn most.
Introduction to Complementary and Alternative Medicine Practices Erica Rooks July 10, 2014 Bachelor’s Capstone in Health & Wellness Kristin Henningsen.
Acupuncture By Katie Hicks.
Practice Key Driver Diagram. Chapter Quality Network ADHD Project Jeff Epstein PhD CQN ADHD National Expert/CQN Data Analyst The mehealth Portal and CQN.
Low Dose Decitabine Versus Best Supportive Care in Elderly Patients with Intermediate or High Risk MDS Not Eligible for Intensive Chemotherapy: Final Results.
S1207: Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients.
HERA TRIAL: 2 Years versus 1 Year of Trastuzumab After Adjuvant Chemotherapy in Women with HER2-Positive Early Breast Cancer at 8 Years of Median Follow-Up.
Responses to Subsequent Anti-HER2 Therapy After Treatment with Trastuzumab-DM1 in Women with HER2- Positive Metastatic Breast Cancer 1 A Phase Ib/II Trial.
Research into Practice Audiology Chemotherapy Ototoxicity Project.
R2 민준기 / 정재헌 교수님. Introduction Patients with resected high-risk locally advanced head and neck cancer –Expect favorable outcomes after concomitant radiochemotherapy(CCRT)
Results of a Phase 2, Multicenter, Single-Arm Study of Eribulin Mesylate as First-Line Therapy for Locally Recurrent or Metastatic HER2-Negative Breast.
MM-005: A Phase 1, Multicenter, Open-Label, Dose-Escalation Study to Determine the Maximum Tolerated Dose for the Combination of Pomalidomide, Bortezomib,
Interventions to Improve Physical Activity and Fatigue for Older Patients Receiving Cancer Treatment Karen M. Mustian, Ph.D., M.P.H. Director and Associate.
SNDA ETHYOL FOR RADIATION INDUCED XEROSTOMIA.
How To Design a Clinical Trial
Alessandra Gennari, MD PhD
Palumbo A et al. Proc ASH 2012;Abstract 200.
Telehealth Mindfulness Meditation Improves
Role of The Physical Therapist in Critical Inquiry
Gajria D et al. Proc SABCS 2010;Abstract P
Quality of Life Assessment
ADSCaN A Randomised Phase II study of Accelerated, Dose escalated, Sequential Chemo-radiotherapy in Non-Small Cell Lung Cancer Rationale: Lung cancer.
Vahdat L et al. Proc SABCS 2012;Abstract P
S1207: Phase III randomized, placebo-controlled trial adding 1 year of everolimus to adjuvant endocrine therapy for patients with high-risk, HR+, HER2-
Bozeman Health Clinical Research
The Nursing Process and Pharmacology Jeanelle F. Jimenez RN, BSN, CCRN
Krop I et al. SABCS 2009;Abstract 5090.
Role of The Physical Therapist in Critical Inquiry
Physical Activity and Endometrial Cancer Survival
Clinical Trials Oct. 6, Lyon France
Presentation transcript:

Integrative Oncology Trials Lorenzo Cohen, PhD Director, Integrative Medicine Program

CAM Use in Oncology (Asking Patients about CAM Use) Patricia Parker, Lorenzo Cohen, Neby Bekele, Jan Pickett, Holly Hough The University of Texas M. D. Anderson Cancer Center Division of Cancer Medicine Community Clinical Oncology Program Research Base

What CIM methods do patients with cancer use? Biologically-based Practices Energy Medicine Mind-Body Medicine Manipulative and Body-Based Practices Whole Medical Systems

CLINICPATIENTSCAM USERS # patients% Breast Clinic GYN Clinic CAM Users Versus Nonusers Navo et al., 2004

Reasons for Using CAM To improve overall health. To reduce adverse drug reactions and/or improve quality of life. To boost the immune system. A minority endorse to treat cancer.

Percent of patients who have not discussed CIM with their doctor Why patients have not discussed CIM with their doctor

National survey of 850 registered nurses involved in direct patient care in oncology settings. Nurses reported that initiated conversations about CAM use were rare. Rojas-Cooley and Grant, 2006 Oncology Nurses and Communicating with Patients about CAM

Primary: Examine efficacy of an educational intervention designed to increase the frequency with which oncology nurses ask their patients about CAM use. Secondary: Examine frequency of CAM use and referral for CAM use in oncology nurses. Evaluate whether personal use among oncology nurses is related to frequency of asking patients about CAM. Assess the frequency and type of CAM use among patients diagnosed with cancer. Study Objectives

Oncology nurses at participating CCOP component sites. Oncology patients of participating providers (4 per provider). Participants

Baseline Patient Assessment Random Assignment to Intervention or Control Provider and Patient Follow-Up Assessment Baseline Provider Assessment Video and Resource List Baseline Provider Assessment Video and Resource List Study Design Provider and Patient Follow-Up Assessment 2 months

Progress 185 patients 8 sites registered

A Phase III Prospective Randomized Trial of Acupuncture for Treatment of Radiation-Induced Xerostomia in Patients with Head and Neck Cancer Joseph Chiang, Mark Chambers, Kay Garcia, Lynn Palmer, Lorenzo Cohen

Background and Significance 70-80% of head/neck cancer patients receive radiation IMRT can reduce physical damage to major salivary glands -Xerostomia still a problem with IMRT

Radiation Treatment and Xerostomia Salivary dysfunction Related to dose, time, location and volume of tissue radiated Develop early in therapy and worsens over time Partially reversible (at <50Gy)

Acupuncture and Xerostomia Acupuncture can stimulate saliva flow Xerostomia relief with as few as 5-10 treatments Benefits lasting up to 3 years post- treatment in one study

Xerostomia Weeks XI Garcia et al., Head & Neck, In Press

Xerostomia Questionnaire * * * * * * * Treatment Week Level (p=0.0005) (p=0.002)

MDASI-H&N MDASI-Symptoms (13 items) MDASI-Interference MDASI-Symptoms (12 items) * * * * * † † † * † (p<0.10) * (p<0.05) * †

* ** * Saliva production in Acupuncture and Control patients * (p<0.05) **(p<0.01) Collected before acu tx (p=0.005) (p=0.007) (p=0.0006) (p=0.005)

Objectives To determine whether or not acupuncture can symptomatically improve severe xerostomia due to head/neck radiotherapy. To explore the duration of response (up to a maximum of 12 weeks) in the subgroup of patients who report a response to the acupuncture intervention.

Inclusion Criteria Patients with head/neck cancer who have received bilateral radiation therapy and who subsequently developed xerostomia. Grade 2 or 3 xerostomia, according to RTOG scale. Nine months after completing radiotherapy. No history of xerostomia prior to the head/neck radiation therapy. No local infection at or near the acupuncture site or active infection. Exclusion Criteria: Patients on or planned to receive another xerostomia treatment agent. All agents known to treat xerostomia should be stopped at least 14 days prior to enrollment.

Acupuncture The acupuncture points will be at three sites on each ear, a site on the chin, a site on each forearm, a site on each hand, a site on each leg, and one placebo needle at Gb32 for a total of 14 sites. All sites will be applied for 20 minutes.

Sham Group (inactive acupuncture) Sham Location 1 - placebo needle at inactive point located 0.5 cun below and 0.5 cun lateral to CV 24 on the chin Sham Location 2 - placebo needle at inactive point located 0.5 cun radial and 0.5 cun proximal to SJ 6 between SJ and LI Channels (bilateral UE) Sham Location 3 - placebo needle at inactive point located 2 cun above Sham Location 2 between SJ and LI Channels and between LI7 and LI8 (bilateral UE) Sham Location 4 - placebo needle at inactive point located 1.0 cun below and 0.5 cun lateral to St 36, between St and Gb Channels (bilateral LE) One 32 gauge x 30mm acupuncture needle at GB32 above the right knee (Note: This point is not indicated for dry mouth and is used to elicit de qi sensation in the control group.) Three 40 gauge x 15mm acupuncture needles on the helix of each ear (6 points total). Location of inactive points will be confirmed with an electrodermal point finder.

Jon Hunter, Lorenzo Cohen, Laszlo Radvanyi, Peter Mueller MDACC CCC Chemotherapy and Mindfulness Relaxation: a Randomized Trial

Side Effects Cytotoxic Nausea and vomiting Alopecia Immunosuppression Anorexia Stomatitis Diarrhea

Side Effects Conditioned Nausea, Vomiting Anxiety Immunosuppression Fatigue (?)

Interventions - General Cognitive/behavioral therapy relaxation guided imagery biofeedback progressive muscle relaxation hypnosis group and individual intervention

Interventions – Nausea and Vomiting guided imagery systematic desensitization hypnosis progressive muscle relaxation

Outcomes Treatment and disease related symptoms Emotional adjustment Functional adjustment Immune function Medical outcomes (chemotherapy dose) Survival?

Therapeutic Barriers Not easily applicable to varied settings or illnesses Typically administered by a trained mental health professional Labor intensive and costly

Attributes of an “Ideal” Intervention Pre-emptive Brief Utilizes available personnel Integrated into standard care Amplifies therapeutic relationship with treatment team Not burdensome for patient Generalizable  to any clinic  to any patient  to any stress

-Mindfulness Relaxation- Self-hypnosis Guided imagery Yoga breathing Mindful attitude Intervention

15-20 minute script first contact requires ~ 60 minutes nurse provides brief educational session (maybe integrated into typical chemotherapy education) runs patient through one training session ‘ troubleshoots” any problems, offers encouragement …. Mindfulness Relaxation Delivery

provides CD for home use (1-2 X per day) subject brings CD to all chemotherapy sessions, using it before and during chemotherapy administration Mindfulness Relaxation Delivery

Relaxation training of patients to be delivered by nurse: to amplify therapeutic alliance, to pre-emptively condition the chemo. setting to relaxation, vs. anxiety and nausea, to embed the intervention in normal process Mindfulness Relaxation Rationale

Design Informed Consent Baseline Assessment Randomization Relaxing Music MR Standard Care Chemotherapy Follow-up

Baseline Middle of course of chemotherapy End of Chemotherapy 3 months after the end of chemotherapy Assessment Schedule

Measures Item Measure N&V Morrow Assessment of Nausea Anxiety STAI Mood POMS Symptoms of Distress SCL-90-R Fatigue MRI-20 Sleep Quality PSQI Quality of LifeFACT-B Immune functionCytotoxicity to K562 target Type-1/Type-2 cytokines WBC/CBC

Nursing Training Protocol Preparation Materials distributed for reading, familiarization of RN.’s with rationale, purpose, methodology of study

Nursing Training Protocol Training Session (1 day) Group session to review written material, communicate the essence of the intervention Review and demonstration of the script Practice sessions, in pairs or small group Review with investigator Refinement and CD production

Nursing Training Protocol Follow-up Principal investigator available ( , telephone) for obstacles, difficulties ‘Refresher’ or ‘trouble-shooting’ sessions: Tele-conference Meetings

Progress 111 patients randomized 11 sites trained